- Home
- KG vs DRTS Comparison
KG vs DRTS Comparison
Compare KG & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KG
- DRTS
- Stock Information
- Founded
- KG N/A
- DRTS 2015
- Country
- KG Bermuda
- DRTS Israel
- Employees
- KG N/A
- DRTS N/A
- Industry
- KG Property-Casualty Insurers
- DRTS Medical/Dental Instruments
- Sector
- KG Finance
- DRTS Health Care
- Exchange
- KG Nasdaq
- DRTS Nasdaq
- Market Cap
- KG 266.5M
- DRTS 300.2M
- IPO Year
- KG N/A
- DRTS N/A
- Fundamental
- Price
- KG $27.20
- DRTS $3.81
- Analyst Decision
- KG
- DRTS Strong Buy
- Analyst Count
- KG 0
- DRTS 1
- Target Price
- KG N/A
- DRTS $9.00
- AVG Volume (30 Days)
- KG 16.6K
- DRTS 63.6K
- Earning Date
- KG 08-15-2025
- DRTS 08-11-2025
- Dividend Yield
- KG N/A
- DRTS N/A
- EPS Growth
- KG N/A
- DRTS N/A
- EPS
- KG N/A
- DRTS N/A
- Revenue
- KG $5,462,137.00
- DRTS N/A
- Revenue This Year
- KG N/A
- DRTS N/A
- Revenue Next Year
- KG N/A
- DRTS N/A
- P/E Ratio
- KG $631.87
- DRTS N/A
- Revenue Growth
- KG 250.18
- DRTS N/A
- 52 Week Low
- KG $20.51
- DRTS $2.11
- 52 Week High
- KG $36.80
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- KG 54.26
- DRTS 66.03
- Support Level
- KG $25.04
- DRTS $3.51
- Resistance Level
- KG $27.42
- DRTS $3.99
- Average True Range (ATR)
- KG 1.46
- DRTS 0.18
- MACD
- KG -0.10
- DRTS 0.04
- Stochastic Oscillator
- KG 57.59
- DRTS 80.00
About KG Kestrel Group Ltd.
Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.